Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Visit https://www.peervoice.com/FED860 to view the entire programme with slides. After completing “Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events”, participants will be able to: Identify adverse events associated with the combination of a nectin-4–directed antibody-drug conjugate (ADC) and a PD-1 inhibitor in patients with locally advanced urothelial carcinoma (IaUC) and metastatic urothelial carcinoma (mUC); and Formulate best practice approaches to the monitoring, identification, and management of adverse events associated with the combination of a nectin-4–directed ADC and a PD-1 inhibitor in patients with IaUC and mUC.

Listen